Despite a rough start in 2015, PCSK9 inhibitors appear to be gaining a little more popularity with payers.
According to a new report by the Institute for Patient Access, payers in 2017 accepted some 3/4 of claims for the drugs, a significant improvement from previous years.
The institute found the inhibitors faced an initial rejection rate of 46 percent, while the final rejection dropped to 26 percent market wide.
Just in 2016, commercial health plans rejected 73 percent of claims; Medicare rejected 39 percent, Symphony Health Solutions reports.
